AA
SPRY icon

ALPS Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

ALPS Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80,830
Closed -$649K – 1211
2026
Q1 		$649K Sell
80,830
-338
-0.4% -$3.24K ﹤0.01% 659
2025
Q4 		$946K Buy
81,168
+31,568
+64% +$307K 0.01% 574
2025
Q3 		$498K Sell
49,600
-3,400
-6% -$48.8K ﹤0.01% 667
2025
Q2 		$925K Buy
+53,000
New +$765K 0.01% 516
2024
Q4 		– Sell
-70,578
Closed -$1.02M – 1038
2024
Q3 		$1.02M Sell
70,578
-5,026
-7% -$59.8K 0.01% 484
2024
Q2 		$643K Buy
75,604
+7,896
+12% +$70.1K ﹤0.01% 544
2024
Q1 		$692K Buy
67,708
+1,312
+2% +$9.78K ﹤0.01% 554
2023
Q4 		$364K Sell
66,396
-4,104
-6% -$18K ﹤0.01% 733
2023
Q3 		$266K Buy
70,500
+838
+1% +$5.5K ﹤0.01% 906
2023
Q2 		$467K Buy
+69,662
New +$465K ﹤0.01% 625

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

ALPS Advisors's SPRY Position: Q2 2026 in Review

ALPS Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 80,830 shares — an estimated $649K sold.

ALPS Advisors first reported a position in SPRY in Q2 2023 and held it in 10 quarters. The position peaked at $1.02M in Q3 2024. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • ALPS Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 80,830 ARS Pharmaceuticals shares in Q2 2026, an estimated $649K.
  • ALPS Advisors first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • ALPS Advisors's ARS Pharmaceuticals position peaked at $1.02M in Q3 2024.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.